Meningococcal B vaccine, Trumenba, now available in Canada
by Press Release from Outbreak News Today on (#3HGZF)
Pfizer Canada Inc. has announced the availability of TRUMENBA (meningococcal group B vaccine) in Canada, following approval by Health Canada in October 2017. TRUMENBA is a vaccine indicated to help prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B bacteria, for individuals 10 through 25 years of age. Invasive meningococcal disease (IMD) is ["]
The post Meningococcal B vaccine, Trumenba, now available in Canada appeared first on Outbreak News Today.